首页 > 期刊杂志 > 正文

LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.

LMO2是T淋巴母细胞白血病/淋巴瘤的特异性标记物

Jevremovic D,Roden AC,Ketterling RP,Kurtin PJ,McPhail ED

Abstract

The diagnosis of T-lymphoblastic leukemia/lymphoma (T-ALL) involving the thymus can be difficult to establish since neoplastic T lymphoblasts show significant phenotypic overlap with both normal thymocytes and thymocytes from epithelial thymic neoplasms (thymomas). LIM Domain Only 2 (LMO2) gene translocations have been implicated in the pathogenesis of a small subset of T-ALLs, and LMO2 protein has recently been reported to be expressed in a large proportion of T-ALLs.
In this study, we tested specificity of LMO2 for distinction between neoplastic and nonneoplastic T-precursor cells in thymus and bone marrow.
Our findings show that LMO2 is expressed in neoplastic lymphoblasts of T-ALL and is absent in thymocytes of normal thymuses or thymomas.
LMO2 is therefore a useful marker for immunophenotypic assessment of thymic neoplasms.

摘要

由于肿瘤性T淋巴母细胞与正常胸腺细胞及来自上皮性胸腺肿瘤(胸腺瘤)的胸腺细胞免疫表型上有重叠,因此,累及胸腺的T淋巴母细胞白血病/淋巴瘤(T-ALL)诊断比较困难。

LMO2基因易位与一小部分T-ALL发病有关,并且最近有文献报道大部分T-ALL存在LMO2蛋白表达。

本研究中,我们检测了胸腺和骨髓中LMO2表达,了解其表达在区分肿瘤性与非肿瘤性T前驱细胞中的特异性。

我们的结果表明LMO2在T-ALL的肿瘤性淋母巴细胞中表达,在正常胸腺或胸腺瘤的胸腺细胞中不表达。

因此,LMO2是胸腺肿瘤免疫表型评估的一个有用指标。

full text

我要评论

0条评论